In contrast to healthy control (HC) and untreated MS groups, CD4+ TEM cells at 4 months post-cladribine (Clad 4M) did not exhibit a preference for migration across the stimulated HBEC monolayer due to fewer CD4+ TEM cells found in the lower chamber relative to the top chamber (Figure 1(Ai)). This evidence concerns the gene CD4 and myeloid sarcoma.